Jane Street Group LLC Reduces Position in Castle Biosciences, Inc. (NASDAQ:CSTL)

Jane Street Group LLC lessened its stake in shares of Castle Biosciences, Inc. (NASDAQ:CSTL) by 59.2% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 59,383 shares of the company’s stock after selling 86,001 shares during the period. Jane Street Group LLC owned approximately 0.21% of Castle Biosciences worth $1,583,000 at the end of the most recent reporting period.

Other large investors also recently bought and sold shares of the company. Covestor Ltd purchased a new stake in Castle Biosciences during the 4th quarter worth approximately $25,000. R Squared Ltd purchased a new stake in shares of Castle Biosciences in the 4th quarter valued at $42,000. KLP Kapitalforvaltning AS purchased a new stake in shares of Castle Biosciences in the 4th quarter valued at $128,000. China Universal Asset Management Co. Ltd. boosted its holdings in shares of Castle Biosciences by 11.3% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 5,939 shares of the company’s stock valued at $158,000 after acquiring an additional 604 shares during the last quarter. Finally, Oak Harvest Investment Services purchased a new stake in shares of Castle Biosciences in the 4th quarter valued at $206,000. Hedge funds and other institutional investors own 92.60% of the company’s stock.

Analysts Set New Price Targets

Several analysts have recently commented on CSTL shares. Canaccord Genuity Group dropped their price objective on shares of Castle Biosciences from $42.00 to $37.00 and set a “buy” rating on the stock in a report on Tuesday, May 6th. Robert W. Baird increased their price target on shares of Castle Biosciences from $36.00 to $37.00 and gave the stock an “outperform” rating in a report on Friday, February 28th. Guggenheim set a $30.00 price target on shares of Castle Biosciences and gave the stock a “buy” rating in a report on Friday, March 28th. Finally, Lake Street Capital lowered their price target on shares of Castle Biosciences from $40.00 to $35.00 and set a “buy” rating on the stock in a report on Tuesday, May 6th. Eight analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $37.50.

Insider Transactions at Castle Biosciences

In other Castle Biosciences news, insider Derek J. Maetzold sold 1,236 shares of the company’s stock in a transaction dated Monday, April 21st. The shares were sold at an average price of $21.52, for a total value of $26,598.72. Following the transaction, the insider now directly owns 74,627 shares in the company, valued at approximately $1,605,973.04. This represents a 1.63% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders sold 27,454 shares of company stock valued at $553,030 in the last 90 days. 7.20% of the stock is currently owned by insiders.

Castle Biosciences Stock Performance

NASDAQ:CSTL opened at $16.75 on Monday. The firm’s fifty day moving average price is $19.49 and its 200 day moving average price is $24.99. Castle Biosciences, Inc. has a 1-year low of $15.70 and a 1-year high of $35.84. The company has a debt-to-equity ratio of 0.02, a current ratio of 7.78 and a quick ratio of 7.64. The firm has a market cap of $483.61 million, a price-to-earnings ratio of 83.75 and a beta of 1.19.

Castle Biosciences (NASDAQ:CSTL) last posted its quarterly earnings data on Monday, May 5th. The company reported ($0.20) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.12). The firm had revenue of $87.99 million during the quarter, compared to analysts’ expectations of $80.40 million. Castle Biosciences had a net margin of 1.95% and a return on equity of 1.47%. On average, sell-side analysts expect that Castle Biosciences, Inc. will post 0.44 EPS for the current year.

Castle Biosciences Company Profile

Castle Biosciences, Inc, a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus.